Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript
Theriva Biologics, Inc. beats earnings expectations. Reported EPS is $-0.34, expectations were $-0.41. Theriva Biologics, Inc.
Theriva Biologics Inc. (TOVX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 57,953 | $24,926 | 0% | |
| 2. | Renaissance Technologies Jim Simons | 59,210 | $25,000 | +10% | 0% |
| 3. | Fisher Asset Management Ken Fisher | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.69 | 14,000 | Officer, Director | 250,000 | 2023-06-07 | Filing | |
| $0.63 | 26,000 | Officer, Director | 236,000 | 2023-06-06 | Filing | |
| $1.04 | 25,000 | Officer, Director | 210,000 | 2023-02-10 | Filing | |
| $0.94 | 25,000 | Officer, Director | 185,000 | 2023-02-02 | Filing | |
| $0.87 | 25,000 | Officer, Director | 160,000 | 2023-01-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.65 | 69,161 | Large Shareholder | 165,332 | 2019-04-03 | Filing | |
| $0.65 | 26,080 | Large Shareholder | 62,342 | 2019-04-03 | Filing | |
| $0.66 | 9,909 | Large Shareholder | 234,493 | 2019-04-02 | Filing | |
| $0.66 | 3,737 | Large Shareholder | 88,422 | 2019-04-02 | Filing | |
| $0.67 | 30,265 | Large Shareholder | 244,402 | 2019-04-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 366,580 | $157,666 | 0% | |
| 2. | 190,060 | $81,745 | 0% | |
| 3. | 141,168 | $60,742 | 0% | |
| 4. | 48,691 | $20,942 | 0% | |
| 5. | 28,528 | $12,270 | 0% |
News See All
Theriva Biologics, Inc. (NYSE:TOVX) Q3 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the Theriva Biologics, Inc. 2023 Third Quarter Operational Highlights and Financial Results.